[A trial of ipratropium bromide dose optimalization in patients with atopic asthma].
The effect of ipratropium bromide inhalation in cumulated doses upon the change of VC, FEV1 and MEF50 was evaluated in 10 patients with atopic bronchial asthma. It was two days examination. On the first day measurements were obtained immediately after inhalation of 2 doses (40 mcg) ipratropium bromide which were repeated in 30 minutes intervals. On the second day measurements were repited after placebo inhalation used in the same intervals. Examinations were finished inhalation of 40 mcg of fenoterol. The study confirms the full effectiveness of high doses of ipratropium bromide in patients with atopic asthma. Improve in spirometric parameters were observed after 40 mcg of ipratropium but the statistically significant differences were found in cumulated doses between 80 and 160 mcg ipratropium bromide without side effects. After fenoterol inhalation further improvement was observed.
Karwat
K
K
Kliniki Pneumonologii, Akademii Medycznej w Warszawie.
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000150:complications / Q000503:physiopathology; D009241:Ipratropium / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012129:Respiratory Function Tests
D001993:Bronchodilator Agents; D009241:Ipratropium